Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ionis Pharmaceuticals (NQ: IONS ) 38.44 +0.49 (+1.29%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ionis Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 Next > Apple To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Monday July 31, 2023 Keybanc cut the price target for Baxter International Inc. (NYSE: BAX) from $53 to $51. Keybanc analyst Matthew Mishan maintained an Overweight rating. Baxter International shares rose 1.2% to $47.58... Via Benzinga BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease July 17, 2023 The companies are working on treatments for a leading cause of heart failure. Via Investor's Business Daily Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment July 03, 2023 Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting Via Benzinga New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy June 30, 2023 From Biogen Inc. Via GlobeNewswire Analyst Expectations for Ionis Pharmaceuticals's Future June 07, 2023 Via Benzinga Recap: Ionis Pharmaceuticals Q1 Earnings May 03, 2023 Via Benzinga Ionis Pharmaceuticals's Earnings Outlook May 02, 2023 Via Benzinga Analyst Expectations for Ionis Pharmaceuticals's Future April 11, 2023 Via Benzinga How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities June 17, 2023 The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... Via Talk Markets Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million June 15, 2023 Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A. Via Investor's Business Daily Hereditary Angioedema Update Solidifies Intellia's Cell Therapy's Competitive Efficacy Profile: Analyst June 12, 2023 Sunday, Intellia Therapeutics Inc (NASDAQ: NTLA) announced updated interim results from the Phase 1 portion of the ongoing Via Benzinga Analyst Creates Bullish Pitch On Ionis Pharmaceuticals Citing 'Strategic Pivot Underway' June 07, 2023 Piper Sandler assumed coverage of Ionis Pharmaceuticals Inc (NASDAQ: IONS) with an Overweight rating and a Via Benzinga Why Ionis Pharmaceutical Shares Are Trading Lower Wednesday June 07, 2023 Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading lower on Wednesday after the company announced plans to offer $500 million of senior convertible notes due in 2028 in a private placement... Via Benzinga Analyst Ratings for Ionis Pharmaceuticals March 21, 2023 Via Benzinga Ionis Pharmaceuticals's Earnings Outlook February 21, 2023 Via Benzinga Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79 May 24, 2023 The Relative Strength Rating for Ionis Pharmaceuticals stock moved into a new percentile Wednesday, as it got a lift from 65 to 79. Via Investor's Business Daily Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023 May 04, 2023 Via Benzinga Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA April 26, 2023 The FDA approved Biogen Inc's (NASDAQ: Via Benzinga What's Going On With Biogen Stock Tuesday? April 25, 2023 Biogen Inc (NASDAQ: BIIB) shares are trading lower Tuesday. The company reported first-quarter results before the bell and the FDA approved its ALS therapy Tuesday afternoon. Via Benzinga Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs April 25, 2023 Via Benzinga 3 Biotech Stocks to Sell Before They’re 6 Feet Under April 24, 2023 Biotech stocks with no earnings, no cash, and no path to profit will have no chance at survival. Here's three such biotech stocks to avoid. Via InvestorPlace AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression April 24, 2023 Via Benzinga Could This Rare-Disease Drug Candidate Become a Blockbuster? April 19, 2023 This drug candidate could be a great treatment option for patients with a potentially deadly disease. Via The Motley Fool Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward' April 12, 2023 SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy... Via Benzinga AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review March 27, 2023 Via Benzinga Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement March 23, 2023 The companies are focusing on a small population of ALS patients with a genetic mutation. Via Investor's Business Daily FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder March 23, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 March 21, 2023 Via Benzinga Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year March 16, 2023 Via Benzinga Analyst Says Ionis' Additional Hereditary Angioedema Study Data Supports 'Highly Competitive Profile' February 21, 2023 Via Benzinga < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.